The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development

Neuromuscular Disorders

Volumn 25, Issue 11, 2015, Pages 827-834

  Vulin, Adeline ^a   Wein, Nicolas ^a   Simmons, Tabatha R ^a   Rutherford, Andrea M ^a   Findlay, Andrew R ^a,b   Yurkoski, Jacqueline A ^a   Kaminoh, Yuuki ^a,c   Flanigan, Kevin M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

Duchenne muscular dystrophy; Duplication; Exon skipping; Mouse model

Indexed keywords

CREATINE KINASE; DYSTROPHIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE DUPLICATION; HOMOLOGOUS RECOMBINATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTRON; MOUSE; MUSCLE NECROSIS; MYOFIBROSIS; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; BODY WEIGHT; GENE TARGETING; GENETICS; MALE; METABOLISM; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; BODY WEIGHT; CREATINE KINASE; DISEASE MODELS, ANIMAL; EXONS; GENE DUPLICATION; GENE KNOCK-IN TECHNIQUES; MALE; MICE, INBRED MDX; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; RNA, MESSENGER;

EID: 84945482820     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.08.005     Document Type: Article

References (22)

1. Dent K.M., Dunn D.M., von Niederhausern A.C., et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005, 134:295-298.
2. Aartsma-Rus A., Van Deutekom J.C., Fokkema I.F., et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006, 34:135-144.
3. Bladen C.L., Salgado D., Monges S., et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015, 36:395-402.
4. Flanigan K.M., Dunn D.M., von Niederhausern A., et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009, 30:1657-1666.
5. Chapman V.M., Miller D.R., Armstrong D., et al. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci U S A 1989, 86:1292-1296.
6. Im W.B., Phelps S.F., Copen E.H., et al. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996, 5:1149-1153.
7. Sharp N.J., Kornegay J.N., Van Camp S.D., et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992, 13:115-121.
8. White S.J., Aartsma-Rus A., Flanigan K.M., et al. Duplications in the DMD gene. Hum Mutat 2006, 27:938-945.
9. Kontgen F., Suss G., Stewart C., et al. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 1993, 5:957-964.
10. Wein N., Vulin A., Falzarano M.S., et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med 2014, 20:992-1000.
11. Radley-Crabb H.G., Fiorotto M.L., Grounds M.D. The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice. PLoS Curr 2011, 3:RRN1276.
12. Goemans N.M., Tulinius M., van den Akker J.T., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011, 364:1513-1522.
13. Mendell J.R., Rodino-Klapac L.R., Sahenk Z., et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013, 74:637-647.
14. Helderman-van den Enden A.T., Straathof C.S., Aartsma-Rus A., et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010, 20:251-254.
15. Aartsma-Rus A., Janson A.A., van Ommen G.J., et al. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 2007, 8:43.
16. Forrest S., Meloni P.L., Muntoni F., et al. Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscul Disord 2010, 20:810-816.
17. Greer K.L., Lochmuller H., Flanigan K., et al. Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids 2014, 3:e155.
18. McArdle A., Edwards R.H., Jackson M.J. How does dystrophin deficiency lead to muscle degeneration? - evidence from the mdx mouse. Neuromuscul Disord 1995, 5:445-456.
19. Flanigan K.M., Wein N., Gurvich O.L., et al. Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscul Disord 2013, 23:192.
20. Flanigan K.M., Dunn D.M., von Niederhausern A., et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 2009, 19:743-748.
21. Gurvich O.L., Maiti B., Weiss R.B., et al. DMD exon 1 truncating point mutations: amelioration of phenotype by alternative translation initiation in exon 6. Hum Mutat 2009, 30:633-640.
22. Chandrasekharan K., Yoon J.H., Xu Y., et al. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med 2010, 2:42ra54.